🇺🇸 Jinshuibao Capsule in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 10

Most-reported reactions

1. Anal Fissure — 1 report (10%)
2. Cataract — 1 report (10%)
3. Cerebral Artery Embolism — 1 report (10%)
4. Constipation — 1 report (10%)
5. Diarrhoea — 1 report (10%)
6. Gastritis Erosive — 1 report (10%)
7. Haemorrhoids — 1 report (10%)
8. Hypokalaemia — 1 report (10%)
9. Memory Impairment — 1 report (10%)
10. Nasopharyngitis — 1 report (10%)

Source database →

Frequently asked questions

Is Jinshuibao Capsule approved in United States?

Jinshuibao Capsule does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Jinshuibao Capsule in United States?

Second Xiangya Hospital of Central South University is the originator. The local marketing authorisation holder may differ — check the official source linked above.